Pyoderma gangrenosum
Pyoderma gangrenosum hè una malatia di a pelle rara è infiammatoria induve i pustuli o i noduli dolorosi diventanu ulcere chì crescenu progressivamente. Pyoderma gangrenosum ùn hè micca infizziosa. I trattamenti ponu includere corticosteroidi, ciclosporina, o diversi anticorpi monoclonali. Ancu s'ella pò affettà e persone di ogni età, affetta soprattuttu e persone trà i 40 è 50 anni.
☆ AI Dermatology — Free Service
In i risultati Stiftung Warentest 2022 da Germania, a satisfaczione di i cunsumatori cù ModelDerm era solu ligeramente più bassu chè cù cunsultazioni di telemedicina pagate.
In i risultati Stiftung Warentest 2022 da Germania, a satisfaczione di i cunsumatori cù ModelDerm era solu ligeramente più bassu chè cù cunsultazioni di telemedicina pagate.
À a perna di una persona cù colite ulcerativa.
relevance score : -100.0%
ReferencesPyoderma gangrenosum hè una cundizione rara di a pelle chì provoca ulcere dolorose cù bordi rossi o violacei. Hè classificatu cum'è una malatia inflamatoria è face parte di un gruppu chjamatu dermatosi neutrofili. A causa di pyoderma gangrenosum hè complessa, chì implica prublemi di l'immunità innata è adattativa in e persone geneticamente propense. Ricertamenti, i circadori anu focu annantu à u folliculu di u pilu cum'è un puntu di partenza potenziale di a malatia.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum hè una cundizione rara di a pelle chì provoca ulcere estremamente dolorose. Mentre a causa ùn hè micca ben capita, sapemu chì implica una attività aumentata di certe cellule immune. U trattamentu di a malatia ùn hè micca sempre faciule. Avemu diverse droghi chì supprimenu u sistema immune o mudificanu a so attività. Accantu à questi, ci focalizemu ancu nantu à u trattamentu di e ferite è a gestione di u dolore. I corticosteroidi è a ciclosporina sò spessu a prima scelta di trattamentu, ma ultimamente ci hè stata più ricerca nantu à l'usu di terapie biologiche cum'è l'inhibitori di TNF-α. Questi biologichi sò sempre più preferiti, in particulare in i malati cù altre cundizioni infiammatorii, è sò aduprati primu in u cursu di a malatia.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
